



## **Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody V<sub>H</sub> development portfolio**

CB693 is a mesothelin targeting, half-life extended, conditional CD137 (4-1BB) agonist

**Cambridge, UK, 6 July 2022** – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the nomination of CB693 as its second proprietary clinical development candidate. CB693 is a mesothelin (MSLN) and CD137 targeting Humabody®, designed for the selective co-stimulation of tumour-specific T cells exclusively within the tumour microenvironment.

CB693 is a potent, half-life extended, bispecific therapeutic candidate that was discovered by Crescendo scientists using next generation sequencing of Humabody V<sub>H</sub> from the Crescendo Mouse and applying a 'straight-to-format' approach. This approach enabled the rapid identification of high affinity MSLN-specific Humabody V<sub>H</sub> and functional screening of the full molecule in *in vitro* and *in vivo* model systems.

"We are very pleased to announce the selection and nomination of the second wholly-owned clinical candidate from our proprietary T cell enhancing CD137 development franchise, and we look forward to driving this exciting molecule towards the clinic," said Philip Bland-Ward, Chief Development Officer at Crescendo Biologics. "The swift identification and optimisation of CB693 provides further proof of the power and potential of our Humabody V<sub>H</sub> platform, and the skill and dedication of our discovery team."

Mesothelin is a clinically validated target for the redirection of immune cells for the treatment of patients with cancer, and mesothelin is preferentially expressed in numerous tumour types, including non-small cell lung cancer and ovarian cancer.

-Ends-

### **For more information, please contact:**

#### **Crescendo Biologics**

Michael Booth, CFO  
+ 44 (0)1223 497140  
[investors@crescendobiologics.com](mailto:investors@crescendobiologics.com)  
[media@crescendobiologics.com](mailto:media@crescendobiologics.com)

#### **Instinctif Partners**

Melanie Toyne-Sewell, Katie Duffell  
+ 44 (0)20 7457 2020  
[crescendo@instinctif.com](mailto:crescendo@instinctif.com)

### **About Crescendo Biologics**

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.



Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours ([NCT04839991](#)). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo's T cell enhancing pipeline.

The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human V<sub>H</sub> domain building blocks (Humabody V<sub>H</sub>). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech; a clinical development partnership for CB213 (a PD-1xLAG-3 multi-specific Humabody) with Cancer Research UK; and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

For more information, please visit [www.crescendobiologics.com](http://www.crescendobiologics.com) and follow [@HUMABODY](#).